Pneumonia Pathogens' Virulence Factors, Patient Inflammatory Markers, and Their Associations With Outcomes
Launched by RUTA NUTAUTIENE · May 30, 2025
Trial Information
Current as of July 01, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The study will assess pneumonia symptoms based on physical examination and additional data (radiological or laboratory tests), supported by prognostic scales such as the Pneumonia Severity Index (PSI), CURB65 (Annexes No. 7 and 8), in combination with biomarkers and inflammatory cytokines. This approach aims to improve decision-making and predict poor outcomes. In the process of lower respiratory tract infections, the level of procalcitonin (PCT) is intended to guide both the initiation and duration of antibiotic therapy. Additionally, treatment may vary depending on the initial levels of i...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years;
- • Diagnosed with community-acquired or hospital-acquired pneumonia;
- • Provides written informed consent.
- Exclusion Criteria:
- • Age under 18;
- • Inability to provide informed consent;
- • Patients with autoimmune diseases;
- • Patients with chronic lung diseases such as cystic fibrosis or COPD;
- • Contraindications to venipuncture.
About Ruta Nutautiene
Ruta Nutautiene is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative study designs and rigorous scientific methodologies. With a focus on fostering collaboration among healthcare professionals, researchers, and regulatory bodies, Ruta Nutautiene strives to facilitate the development of novel therapies and treatments across various therapeutic areas. The organization emphasizes ethical practices, patient safety, and adherence to regulatory standards, ensuring that all clinical trials are conducted with the highest level of integrity and transparency. Through its commitment to excellence, Ruta Nutautiene aims to contribute significantly to the evolving landscape of healthcare and clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kaunas, , Lithuania
Patients applied
Trial Officials
Astra Vitkauskiene, prof. dr., MD, PhD
Study Director
Lithuanian University of Health Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported